Study reveals why many opt out of multiplex testing for cancer-related gene variants
the ONA take:
Many patients do not want the information that comprehensive genetic testing provides, according to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania and the Basser Center for BRCA in Penn’s Abramson Cancer Center.
In the study, 49 patient participants with a family or personal history that increased their risk for developing breast and other forms of cancer were offered multiplex testing. More than one-third of the participants declined the test because of uncertainty of the results.
Multiplex testing allows for simultaneous analysis of alterations in multiple cancer-related genes, whereas targeted testing focuses on a specific genetic mutations (eg, BRCA1 and BRCA2 gene mutations). However, the significance of alterations in many of the genes analyzed in multiplex testing is unknown.
All 49 participants received counseling on the advantages and disadvantages of the tests. After counseling, 16 participants declined multiplex testing or being told their results.
Of the remaining participants, 16 tested negative for any cancer-related variants, five tested positive, and 12 were found to have gene variants of uncertain significance (meaning that whether the changes are benign or tied to cancers is unclear).
Many patients do not want the information that comprehensive genetic testing provides.
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Coping With Lymphedema: A Patient Guide (Fact Sheet)
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|